Dr. Debu Tripathy discusses the FDA approval of Enhertu in unresectable or metastatic hormone receptor HR+, HER2-low or ...

Dr. Debu Tripathy discussed the importance of understanding the distinctions between HER2-low and HER2-ultralow breast cancer ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) has received approval from the US Food and Drug Administration (FDA) for an expanded indication of ...

There are no targeted therapies specifically approved for patients with HER2-ultra-low expression, and approval would move Enhertu up the treatment pathway ahead of chemo. The results reported at ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

Patients with tumours that are HER2-low or HER2-ultralow now have more options to consider with their healthcare team.” In the trial, Enhertu showed a 36% reduction in the risk of disease progression ...

Enhertu is a HER2-directed antibody and topoisomerase ... Study participants with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer who disease had progressed on endocrine therapy ...